IL289784A - isoqc and/or qc enzyme inhibitors - Google Patents
isoqc and/or qc enzyme inhibitorsInfo
- Publication number
- IL289784A IL289784A IL289784A IL28978422A IL289784A IL 289784 A IL289784 A IL 289784A IL 289784 A IL289784 A IL 289784A IL 28978422 A IL28978422 A IL 28978422A IL 289784 A IL289784 A IL 289784A
- Authority
- IL
- Israel
- Prior art keywords
- isoqc
- pyrrolidine
- inhibitors
- fused
- enzyme
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185997 | 2019-07-12 | ||
| PCT/EP2020/069630 WO2021009068A1 (en) | 2019-07-12 | 2020-07-10 | N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289784A true IL289784A (en) | 2022-03-01 |
Family
ID=67262155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289784A IL289784A (en) | 2019-07-12 | 2022-01-12 | isoqc and/or qc enzyme inhibitors |
Country Status (12)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717089A3 (en) | 2021-08-02 | 2026-06-24 | Syngenta Crop Protection AG | Microbiocidal pyrazole derivatives |
| AU2022203580A1 (en) * | 2021-09-17 | 2023-04-06 | Academia Sinica | Methods of Increasing Cell Phagocytosis |
| EP4447682A1 (en) | 2021-12-17 | 2024-10-23 | Syngenta Crop Protection AG | Microbiocidal pyrazole derivatives |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| PY2403614A (es) | 2023-01-27 | 2025-09-11 | Syngenta Crop Protection Ag | Derivados de pirazol microbiocidas |
| PY2404467A (es) | 2023-02-01 | 2025-03-31 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| EP4455142A1 (en) | 2023-04-26 | 2024-10-30 | Scenic Immunology B.V. | Novel inhibitor of qpctl and/or qc |
| PY2447478A (es) | 2023-06-14 | 2025-03-18 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| AR134999A1 (es) | 2024-02-02 | 2026-05-20 | Syngenta Crop Protection Ag | Derivados de pirazol microbiocidas |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
| WO2026022173A1 (en) | 2024-07-26 | 2026-01-29 | Syngenta Crop Protection Ag | Microbiocidal pyrazole compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011002106A (es) * | 2008-09-04 | 2011-04-07 | Probiodrug Ag | Inhibidores novedosos. |
| US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| AU2014272695B2 (en) * | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| WO2019022600A1 (en) * | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47 |
-
2020
- 2020-07-10 CA CA3147154A patent/CA3147154A1/en active Pending
- 2020-07-10 BR BR112022000505A patent/BR112022000505A8/pt unknown
- 2020-07-10 US US17/626,614 patent/US20230077723A1/en not_active Abandoned
- 2020-07-10 KR KR1020227004600A patent/KR20220054293A/ko not_active Ceased
- 2020-07-10 CN CN202080056962.2A patent/CN114466849B/zh not_active Expired - Fee Related
- 2020-07-10 PH PH1/2022/550079A patent/PH12022550079A1/en unknown
- 2020-07-10 MX MX2022000521A patent/MX2022000521A/es unknown
- 2020-07-10 JP JP2022501167A patent/JP2022542540A/ja active Pending
- 2020-07-10 EP EP20743091.9A patent/EP3997091A1/en not_active Withdrawn
- 2020-07-10 AU AU2020312647A patent/AU2020312647A1/en not_active Abandoned
- 2020-07-10 WO PCT/EP2020/069630 patent/WO2021009068A1/en not_active Ceased
-
2022
- 2022-01-12 IL IL289784A patent/IL289784A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3997091A1 (en) | 2022-05-18 |
| MX2022000521A (es) | 2022-06-14 |
| PH12022550079A1 (en) | 2023-04-12 |
| BR112022000505A2 (pt) | 2022-03-22 |
| BR112022000505A8 (pt) | 2022-04-12 |
| CN114466849A (zh) | 2022-05-10 |
| CN114466849B (zh) | 2024-07-12 |
| AU2020312647A1 (en) | 2022-02-24 |
| KR20220054293A (ko) | 2022-05-02 |
| WO2021009068A1 (en) | 2021-01-21 |
| US20230077723A1 (en) | 2023-03-16 |
| JP2022542540A (ja) | 2022-10-05 |
| CA3147154A1 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279173A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL280762A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| EP3990448A4 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | |
| EP3672973A4 (en) | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USING THEREOF | |
| EP3797109A4 (en) | HETEROCYCLIC COMPOUNDS AS KINAS INHIBITORS, COMPOSITIONS CONTAINING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| EP3962484A4 (en) | RAF KINASE INHIBITORS | |
| EP3697791A4 (en) | HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING A HETEROCYCLIC COMPOUND, AND METHODS OF USING THEREOF | |
| IL287026A (en) | Heterocyclic compounds and their uses | |
| EP4041198A4 (en) | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF | |
| EP3448852A4 (en) | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL | |
| EP3882247A4 (en) | SIX-MEMBERED, SIX-MEMBERED, HETEROCYCLIC COMPOUND AND USES OF THEREOF AS A PROTEIN KINASE RECEPTOR INHIBITOR | |
| IL289783A (en) | enzyme inhibitors | |
| TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| IL281742A (en) | Novel compounds as nadph oxidase inhibitors | |
| EP3744722A4 (en) | Ss-LACTAMASE INHIBITOR AND ITS USE | |
| MX2023001805A (es) | Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida. | |
| EP3999064A4 (en) | Inhibitors of tyrosine kinase | |
| EP3266265A4 (en) | Offloading of controlling across access nodes | |
| EA202091691A1 (ru) | ТВЕРДЫЕ ФОРМЫ ЗАМЕЩЕННЫХ 5,6-ДИГИДРО-6-ФЕНИЛБЕНЗО[f]ИЗОХИНОЛИН-2-АМИНОВЫХ СОЕДИНЕНИЙ | |
| EP3697416A4 (en) | INHIBITORS OF THE MUTED TYROSINE KINASES OF THE EGFR FAMILY | |
| EP3909952A4 (en) | SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF | |
| HK40071644A (en) | Heterocyclic inhibitors of tyrosine kinase | |
| AU2017900935A0 (en) | Heterocyclic inhibitors of PCSK9 | |
| HK40061556A (en) | Heterocyclic kinase inhibitors and uses thereof |